Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ionctura | AbbVie Inc | Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2025
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ionctura | AbbVie Inc | Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib,Docetaxel,Dostarlimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
iOnctura Commences Randomized Phase I/II study in Non-Small Cell Lung Cancer
Details : IOA-244 (roginolisib) is an orally dosed small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Roginolisib,Docetaxel,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
iOnctura Commences Randomized Phase II Study in Metastatic Uveal Melanoma
Details : IOA-244 (roginolisib) is an orally dosed small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of metastatic uveal melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
iOnctura Reaches New Clinical Milestones in Uveal Melanoma
Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of cutaneous melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Roginolisib,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Details : Roginolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uveal Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib,Dostarlimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
iOnctura Announces Expansion of Roginolisib Clinical Trial Program to NSCLC
Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2024
Lead Product(s) : Roginolisib,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Syncona Limited
Deal Size : $85.9 million
Deal Type : Series B Financing
iOnctura Announces €80 Million Series B Financing to Progress Pipeline Through Phase II
Details : The financing will be used to accelerate the development of IOA-244 (roginolisib), which is being evaluated in the mid-stage clinical trial studies for the treatment of uveal melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 20, 2024
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Syncona Limited
Deal Size : $85.9 million
Deal Type : Series B Financing
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of metastatic uveal melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : Roginolisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable